“
“<sec id=”section1-0267659113481398″> Objective:\n\nA perioperative cardiac events is one of the most important medical concerns for both surgeons and patients. The purpose of the current study was to determine the prognostic value of myocardial

perfusion imaging (MPI), using dipyridamole 99m Tc-MIBI, for the prediction of perioperative cardiac events.\n\n<sec id=”section2-0267659113481398″> Materials and methods:\n\nThis ACY-738 chemical structure study included 253 patients who were candidates for non-cardiac elective surgery and underwent scanning with dipyridamole 99m Tc-MIBI. Based on normal or abnormal MPI, patients were divided into two groups and all preoperative cardiac events Bcl-2 cancer were recorded. Risk factors, including diabetes mellitus, dyslipidemia, hypertension, smoking and age 70 years, were compared between patients with normal and abnormal MPI and, also, in patients with or without cardiac events.\n\n<sec id=”section3-0267659113481398″> Results:\n\nThere were 197 patients with normal and 56 patients with abnormal MPI. In total, 14 patients had perioperative cardiac events, which included myocardial infarction (MI), hypotension, arrhythmia and death; of the 14 patients

with perioperative cardiac events, 12 had abnormal and two had normal MPI. There were statistically meaningful differences between the two groups (p<0.001). Based on these findings, we determined that MPI had a sensitivity of 85.7%, a specificity of 81.6%, an accuracy of 81.8%, a positive predictive value of 21.4 % and a negative predictive value of 98.9%.\n\n<sec id=”section4-0267659113481398″> Conclusion:\n\nThe incidence of perioperative cardiac events is higher in patients with abnormal MPI. Dipyridamole 99m Tc-MIBI myocardial perfusion imaging can accurately detect the preoperative cardiac risk of patients undergoing major non-cardiac surgery. Based on these findings, the occurrence of perioperative cardiac events in patients with abnormal MPI should

be considered, especially in the older age population (age 70).”
“Recently, we reported a number of key, common medications that affect the air passages in a variety of fashions. The purpose of this article is to provide a comprehensive review selleck products of the literature on the subject, including supportive articles published in languages other than English. The presented information was gathered by a review of the English literature, by cross referencing, and by communication with other interventional pulmonologists. We identified several additional medications causing either direct or systemic effects on the air passages. In this review, we update the clinical presentation, mechanism of injury, diagnosis, and management of the airway complications related to these medications.